三重阴性乳腺癌:瘤免疫性及其他方面
Elio Ibrahim1, Ernest Diab1,2, Rony Hayek1
1Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
International journal of breast cancer
|October 14, 2024
概括
三阴性乳腺癌 (TNBC) 是具有攻击性和难以治疗的. 这次审查涵盖了TNBC.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 三阴性乳腺癌 (TNBC) 由于其具有攻击性和有限的治疗途径,因此具有重大临床挑战.
- 在临床,遗传病学和分子层面上,TNBC的特点是显著的异质性,使治疗策略复杂化.
研究的目的:
- 审查TNBC的免疫特征.
- 讨论目前和新兴的TNBC免疫疗法在不同的疾病环境.
- 探索新的治疗策略和TNBC治疗的未来挑战.
主要方法:
- 文献综述侧重于免疫疗法,抗体-药物联合体 (ADC) 和多ADP-ribose聚合酶 (PARP) 抑制剂在TNBC中.
- 分析与TNBC异质性相关的临床,本病理和分子数据.
- 综合当前的护理标准和正在进行的研究结果.
主要成果:
- TNBC具有独特的免疫原性特征,这些特征正在被新型疗法所准.
- 免疫疗法在新辅助,辅助和转移性TNBC的设置中显示出希望.
- 目前正在进行的研究正在探索ADC,PARP抑制剂和组合疗法.
结论:
- 了解TNBC异质性对于有效治疗至关重要.
- 免疫疗法和针对性药物,如ADC和PARP抑制剂,是改善TNBC结果的有希望的途径.
- 应对未来的挑战对于推进TNBC护理至关重要.
相关概念视频
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Cytotoxic T Cells-mediated Immune Response
857
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
857


